Evidence map›Paper›PMID 37668219›Full record

ArticleIUCrJ2023

The structure of AcrIC9 revealing the putative inhibitory mechanism of AcrIC9 against the type IC CRISPR-Cas system.

Yong Jun Kang, Ju Hyeong Kim, Gwan Hee Lee, Hyun Ji Ha, Young Hoon Park, Eunmi Hong, Hyun Ho Park

Open access · goldAbstract read
In one paragraph

Article in IUCrJ, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 72% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 0 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Yong Jun KangCollege of Pharmacy, Chung-Ang University, Seoul 06974, Republic of Korea.
Ju Hyeong KimCollege of Pharmacy, Chung-Ang University, Seoul 06974, Republic of Korea.
Gwan Hee LeeCollege of Pharmacy, Chung-Ang University, Seoul 06974, Republic of Korea.
Hyun Ji HaCollege of Pharmacy, Chung-Ang University, Seoul 06974, Republic of Korea.
Young Hoon ParkNew Drug Development Center, Daegu-Gyeongbuk Medical Innovation Foundation, Daegu 41061, Republic of Korea.
Eunmi HongNew Drug Development Center, Daegu-Gyeongbuk Medical Innovation Foundation, Daegu 41061, Republic of Korea.
Hyun Ho ParkCollege of Pharmacy, Chung-Ang University, Seoul 06974, Republic of Korea.ORCID 0000-0001-9928-0847
Chung-Ang University · KRDaegu-Gyeongbuk Medical Innovation Foundation · KR

Funding

Ministry of Trade, Industry and Energy, Korea Evaluation Institute of Industrial Technology 20020237National Research Foundation of Korea 2018R1A4A1023822National Research Foundation of Korea 2021R1A2C3003331
6 · The paper itself

Abstract

CRISPR-Cas systems are known to be part of the bacterial adaptive immune system that provides resistance against intruders such as viruses, phages and other mobile genetic elements. To combat this bacterial defense mechanism, phages encode inhibitors called Acrs (anti-CRISPR proteins) that can suppress them. AcrIC9 is the most recently identified member of the AcrIC family that inhibits the type IC CRISPR-Cas system. Here, the crystal structure of AcrIC9 from Rhodobacter capsulatus is reported, which comprises a novel fold made of three central antiparallel β-strands surrounded by three α-helixes, a structure that has not been detected before. It is also shown that AcrIC9 can form a dimer via disulfide bonds generated by the Cys69 residue. Finally, it is revealed that AcrIC9 directly binds to the type IC cascade. Analysis and comparison of its structure with structural homologs indicate that AcrIC9 belongs to DNA-mimic Acrs that directly bind to the cascade complex and hinder the target DNA from binding to the cascade.

Indexed as

BacteriophagesRhodobacter capsulatusCRISPR-Cas SystemsPolymersProtein DomainsPolymersAcrIC9anti-CRISPRbacterial immunityCRISPR–Cas systemsDNA-mimic Acrsinhibitory mechanismstype IC cascades

Identifiers

PMID37668219
PMCPMC10478522
OpenAlexW4386349920

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.